China’s First Antitrust Enforcement Case Targeting Individual Liability: Strategic Guidance for Multinational Corporations
By EsqSocial Corporation 08/05/25
The Administration for Market Regulation of Shanghai recently finalized penalties totaling RMB 223 million (approx. $31 million) against three pharmaceutical companies for colluding to fix prices and divide markets for methanesulfonic acid neostigmine injection, a critical drug in anesthesia and emergency care (Product Involved). This landmark case marks the first application of the individual liability for monopoly agreement provision under China’s Anti-Monopoly Law (AML), penalizing both...
By: Morgan Lewis